8-K

                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D. C. 20549



                            FORM 8-K

                         CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
                              1934



Date of Report (Date of earliest event reported): February 27, 2004



                      HEMACARE CORPORATION
     (Exact Name of Registrant as Specified in its Charter)



                           CALIFORNIA
         (State or Other Jurisdiction of Incorporation)



         000-15223                        95-3280412
    (Commission File No.)    (I.R.S. Employer Identification No.)



                       21101 Oxnard Street
                    Woodland Hills, CA 91367
       (Address of principal executive offices) (Zip Code)



Registrant's telephone number, including area code: (818) 226-1968

                                 -1-
  2


ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number    Description
- --------------    ---------------------------------------------
99.1              Press Release issued by HemaCare, dated February
                  27, 2004

ITEM 9.  REGULATION FD DISCLOSURE

On February 27, 2004, HemaCare Corporation issued a press release
announcing the date of its 2004 annual meeting of shareholders
(the "Meeting") and the record date thereof.  A copy is attached
as Exhibit 99.1 to this report and is incorporated herein by
reference.

Under certain circumstances, shareholders are entitled to present
proposals at shareholder meetings.  SEC rules provide that in the
event that the date of an annual meeting is advanced or delayed
more than 30 days from the date of the prior year's annual
meeting, shareholder proposals intended to be included in the
proxy statement must be received within a reasonable time before
the Company begins to print and mail the proxy statement for the
annual meeting.  The Meeting will be held on May 25, 2004. The
prior year's annual meeting was held on August 13, 2003.  It is
anticipated that the proxy statement relating to the Meeting will
be mailed to shareholders on or about April 10, 2004.

SEC rules also govern the Company's ability to use discretionary
proxy authority with respect to shareholder proposals that were
not submitted by the shareholders in time to be included in the
proxy statement.  In the event a shareholder proposal is not
submitted to the Company within a reasonable time before the
Company begins to print and mail the proxy statement for the
Meeting, the proxies solicited by the Board of Directors will
confer authority on the proxyholders to vote the shares in
accordance with their best judgment and discretion.

The Company's Bylaws provide that a shareholder may nominate a
person for election as a director at a meeting only if written
notice of the shareholder's intent to make such nomination has
been given to the Secretary of the Company no later than the
latter to occur of either  (a) 90 days in advance of such meeting
or (b) the seventh day following the first public announcement of
the date of such meeting.  Each such notice must include: (1) the
name and address of the shareholder who intends to make the
nomination and the name and address of the person or persons to
be nominated; (2) a representation that the shareholder is a
beneficial owner of stock of the Company entitled to vote at the
meeting, and that the shareholder intends to appear in person or
by proxy at the meeting and to nominate the person or persons
specified in the notice; (3) a description of all arrangements or
understandings between the shareholder and each nominee and any
other person or persons (naming such person or persons) pursuant
to which the nomination or nominations are to be made by the
shareholders; (4) such other information regarding each nominee
proposed by such shareholder as would be required to be included
in the proxy statement filed pursuant to the proxy rules of the
SEC, had the nominee been nominated, or intended to be nominated,
by the Board of Directors; and (5) the consent of each intended

                               -2-
  3


nominee named in the notice to serve as a director of the Company
if so elected.  In addition, the shareholder making such
nomination shall promptly provide any other information
reasonably requested by the Company.  The chairman of any meeting
of shareholders shall direct that any nomination not made in
accordance with the foregoing procedures will be disregarded

The Company's Bylaws provide that a shareholder who wishes to
present a proposal at the shareholder meeting must, among other
things, (i) given written notice of the proposal to the Secretary
of the Company not less than 90 days before the meeting or, if
later, the seventh day following the first public announcement of
the date of the meeting; (ii) a brief description of the proposal
and the reasons for conducting such business at the meeting;
(iii) the name and address as they appear on the Company's books
of the shareholder proposing such business; (iv) the class and
number of shares of the Company which are beneficially owned by
the shareholder; and (v) any material interest of the shareholder
in such business.  In addition, the shareholder making such
proposal shall promptly provide any other information reasonably
required by the Company.

The information in this Current Report on Form 8-K, including the
exhibits, will not be treated as "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to the liabilities of that section.
This information will not be incorporated by reference into a
filing under the Securities Act of 1933, or into another filing
under the Exchange Act, unless that filing expressly refers to
specific information in this report.

                           SIGNATURES

Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the registrant has duly caused this report to be signed  on
its behalf by the undersigned hereunto duly authorized.



Date: February  27,   2004   HEMACARE CORPORATION

                             By: /s/ Judi Irving
                             --------------------------------
                             Judi Irving
                             Chief Executive Officer


                             -3-

 4

                          EXHIBIT INDEX

Exhibit Number   Description
- --------------   -------------------------------------------------
   99.1          Press Release issued by HemaCare, dated
                 February 27, 2004



                            -4-

EX-99

                                            EXHIBIT 99.1

                               [LOGO]

                       N E W S   R E L E A S E


For Immediate Release

Contact:  HemaCare Corporation
          JoAnn Mannise, Director of Investor Relations
          877-310-0717
          www.hemacare.com

RELEASE DATE:  February 27, 2004

             HEMACARE CORPORATION SETS DATE FOR ITS 2004
                     ANNUAL SHAREHOLDERS MEETING


     LOS  ANGELES  ------ HemaCare Corporation (OTC  Bulletin  Board:
HEMA)  announced  today that its 2004 annual meeting of  shareholders
(the  "Meeting") will be held on Tuesday, May 25, 2004, at 9:00  a.m.
(local time) at the Company's corporate headquarters located at 21101
Oxnard  Street, Woodland Hills, California 91367.  Only  shareholders
of  record at the close of business on April 7, 2004 ("Shareholders")
will be entitled to notice of and to vote, in person or by proxy,  at
the  Meeting  or  any  adjournment or postponement  thereof.   It  is
expected  that  the proxy statement relating to the Meeting  will  be
mailed to Shareholders on or about April 10, 2004.

                     About HemaCare Corporation

     Founded  in  1978,  HemaCare  is a national  provider  of  blood
products and services and the only publicly traded company engaged in
the  blood services industry in the U.S.  HemaCare is licensed by the
FDA  and accredited by the American Association of Blood Banks.   The
Company  focuses on providing cost effective, high quality  solutions
to the blood-related needs of U.S. hospitals.

    This  press release contains "forward-looking statements" within
the  meaning of the term in the Private Securities Litigation  Reform
Act  of 1995 (Section 27A of the Securities Exchange Act of 1933,  as
amended,  and Section 21E of the Securities Exchange Act of 1934,  as
amended).  Additional written or oral forward-looking statements  may
be  made  by  the  Company  from time to time  in  filings  with  the
Securities   and   Exchange  Commission  or  otherwise.    Statements
contained  herein  that are not historical facts are  forward-looking
statements  pursuant to the safe harbor provisions referenced  above.
Forward-looking  statements  are  inherently  subject  to  risks  and
uncertainties  some of which cannot be predicted or quantified  based
on  current  expectations.   Such risks  and  uncertainties  include,
without  limitation, the risks and uncertainties set forth from  time
to  time  in  reports  filed by the Company with the  Securities  and
Exchange   Commission.   Although  the  Company  believes  that   the
expectations   reflected  in  such  forward-looking  statements   are
reasonable,  it  can  give no assurance that such  expectations  will
prove  to have been correct.  Consequently, future events and  actual
results could differ materially from those set forth in, contemplated
by,  or  underlined the forward-looking statements contained  herein.
The Company undertakes no obligation to publicly release any revision
to  these  forward  looking  statements made  to  reflect  events  or
circumstances after the date here of.

                                 ###